310 related articles for article (PubMed ID: 19107482)
1. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type.
Yong W; Zheng W; Zhu J; Zhang Y; Wang X; Xie Y; Lin N; Xu B; Lu A; Li J
Ann Hematol; 2009 Jul; 88(7):647-52. PubMed ID: 19107482
[TBL] [Abstract][Full Text] [Related]
2. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
3. A five
Vittayawacharin P; Khuhapinant A
Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
5. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
[TBL] [Abstract][Full Text] [Related]
8. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
Zhang XX; Xie CH; Xu Y; Deng D; Zhao YH; Zou BW; Zhou L; Li M; Wang J; Liu WP; Huang MJ
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):747-52. PubMed ID: 19304409
[TBL] [Abstract][Full Text] [Related]
9. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
10. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
11. PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Zheng W; Gao Y; Ke X; Zhang W; Su L; Ren H; Lin N; Xie Y; Tu M; Liu W; Ping L; Ying Z; Zhang C; Deng L; Wang X; Song Y; Zhu J
BMC Cancer; 2018 Sep; 18(1):910. PubMed ID: 30241515
[TBL] [Abstract][Full Text] [Related]
12. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A; Gachard N; Marin B; Rogez S; Audrain M; Suarez F; Tilly H; Morschhauser F; Thieblemont C; Ysebaert L; Devidas A; Petit B; de Leval L; Gaulard P; Feuillard J; Bordessoule D; Hermine O;
Blood; 2011 Feb; 117(6):1834-9. PubMed ID: 21123825
[TBL] [Abstract][Full Text] [Related]
14. [Clinical differences between primary nasopharyngeal NK/T-cell lymphoma and primary nasal cavity NK/T-cell lymphoma with nasopharynx extension].
Liu WX; Liu YP; Jin J; Wang SL; Fang H; Ren H; Song YW; Chen B; Lu NN; Li N; Tang Y; Qi SN; Tang Y; Wang WH; Li YX
Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):56-62. PubMed ID: 30678418
[No Abstract] [Full Text] [Related]
15. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
Yokoyama H; Yamamoto J; Tohmiya Y; Yamada MF; Ohguchi H; Ohnishi Y; Okitsu Y; Fukuhara N; Ohba-Ohtsuka R; Kohata K; Ishizawa K; Kameoka J; Harigae H
Leuk Lymphoma; 2010 Aug; 51(8):1509-12. PubMed ID: 20496989
[TBL] [Abstract][Full Text] [Related]
16. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma.
Yong W; Zheng W; Zhang Y; Zhu J; Wei Y; Zhu D; Li J
Int J Hematol; 2003 Aug; 78(2):163-7. PubMed ID: 12953813
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective analyses of CHOPE plus L-asparaginase regimen in treatment of T-cell lymphoma].
Wan WL; Wang J; Zhu MX; Zhang W; Ke XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):841-845. PubMed ID: 27752167
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
[TBL] [Abstract][Full Text] [Related]
19. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Jaccard A; Petit B; Girault S; Suarez F; Gressin R; Zini JM; Coiteux V; Larroche C; Devidas A; Thiéblemont C; Gaulard P; Marin B; Gachard N; Bordessoule D; Hermine O
Ann Oncol; 2009 Jan; 20(1):110-6. PubMed ID: 18701429
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Ahn HK; Kim SJ; Hwang DW; Ko YH; Tang T; Lim ST; Kim WS
Invest New Drugs; 2013 Apr; 31(2):469-72. PubMed ID: 23108598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
